Skip to contentS
Strata Critical Medical, Inc.
S
SRTAStrata Critical Medical, Inc. Q2 2024 · 10-Q
Revenue$67.95M$67.95M+11.4% vs Q2 2023 Net Income-$11.33M-$11.33MN/M vs Q2 2023 EPS Diluted-$0.15-$0.15N/M vs Q2 2023 Operating Income-$12,149,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Strata Critical Medical, Inc. · CIK 1779128 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,734,000N/M Margins · derivedOperating margin-17.9%+2.1 pt vs Q2 2023
Net margin-16.7%+3.4 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end